National Research Co. (NASDAQ:NRC) Major Shareholder Sells $310,397.88 in Stock

National Research Co. (NASDAQ:NRC) major shareholder Amandla Mk Trust sold 4,853 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $63.96, for a total transaction of $310,397.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Amandla Mk Trust also recently made the following trade(s):

  • On Wednesday, November 27th, Amandla Mk Trust sold 2,600 shares of National Research stock. The shares were sold at an average price of $64.01, for a total transaction of $166,426.00.
  • On Monday, November 25th, Amandla Mk Trust sold 4,445 shares of National Research stock. The shares were sold at an average price of $63.95, for a total transaction of $284,257.75.
  • On Thursday, November 21st, Amandla Mk Trust sold 1,565 shares of National Research stock. The shares were sold at an average price of $63.81, for a total transaction of $99,862.65.
  • On Wednesday, September 18th, Amandla Mk Trust sold 500,000 shares of National Research stock. The shares were sold at an average price of $60.50, for a total transaction of $30,250,000.00.
  • On Tuesday, September 3rd, Amandla Mk Trust sold 33,800 shares of National Research stock. The stock was sold at an average price of $64.84, for a total transaction of $2,191,592.00.

NRC stock traded down $1.10 on Monday, hitting $63.41. 19,305 shares of the company were exchanged, compared to its average volume of 38,139. National Research Co. has a twelve month low of $35.72 and a twelve month high of $68.86. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.69 and a quick ratio of 0.69. The business’s fifty day moving average is $59.58 and its two-hundred day moving average is $46.71. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 60.97 and a beta of 0.79.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Tuesday, December 31st will be given a dividend of $0.21 per share. This is a positive change from National Research’s previous quarterly dividend of $0.19. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.84 annualized dividend and a yield of 1.32%. National Research’s dividend payout ratio is 73.08%.

A number of hedge funds have recently modified their holdings of NRC. Vanguard Group Inc. increased its position in National Research by 10.3% during the second quarter. Vanguard Group Inc. now owns 562,951 shares of the company’s stock worth $32,421,000 after purchasing an additional 52,656 shares during the last quarter. Nuveen Asset Management LLC acquired a new stake in shares of National Research in the second quarter worth $2,920,000. BlackRock Inc. increased its position in shares of National Research by 7.5% in the second quarter. BlackRock Inc. now owns 709,948 shares of the company’s stock worth $40,885,000 after acquiring an additional 49,361 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of National Research by 4.3% in the second quarter. Renaissance Technologies LLC now owns 513,800 shares of the company’s stock worth $29,590,000 after acquiring an additional 21,100 shares in the last quarter. Finally, First Quadrant L P CA increased its position in shares of National Research by 802.8% in the third quarter. First Quadrant L P CA now owns 18,471 shares of the company’s stock worth $1,067,000 after acquiring an additional 16,425 shares in the last quarter. 39.67% of the stock is owned by hedge funds and other institutional investors.

Separately, ValuEngine lowered shares of National Research from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Further Reading: Find a Trading Strategy That Works

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.